12:27 PM EDT, 04/24/2024 (MT Newswires) -- CureVac ( CVAC ) said Wednesday it initiated the early stage portion of a broader study into an investigational flu vaccine developed with GSK (GSK).

The phase 1 trial is part of a combined phase 1/2 study of the vaccine candidate which will target the H5N1 strain, a potential future pandemic threat.

The company will evaluate up to five dose levels of the vaccine in the study, which will take place in the US.

CureVac ( CVAC ) shares were down 6.6% in recent Wednesday trading.

Price: 2.43, Change: -0.18, Percent Change: -6.73